Skip to main content
. 2013 Jan;23(1):58–63. doi: 10.1089/thy.2011.0487

FIG. 1.

FIG. 1.

Description of the study cohort. This algorithm demonstrates how the final inclusion of patients was determined. Seventy-six patients with structural recurrences detected on neck US or CT scan and any other imaging performed as part of the clinical evaluation 1 year after remnant ablation, 6 who received empirical RAI therapy and 21 without available follow-up sTg were excluded. Patients were classified into three groups according to sTg1 concentrations: (A) 2–4.9 ng/mL, (B) 5–19.9 ng/mL, (C) ≥20 ng/mL. RRA, radioactive iodine remnant ablation; sTg, stimulated thyroglobulin; RxWBs, post-treatment whole-body scan; TgAb, anti-thyroglobulin antibody; sTg1, sTg measured 1 year after total thyroidectomy and remnant ablation; sTg2, sTg measured 1–2 years after sTg1; US, ultrasonography; FDG-PET, fluorodeoxyglucose positron emission tomography; CT, computed tomogram; RAI, radioactive iodine; BR, biochemical remission; NSED, no structural evidence of disease.